Psoriasis: risankizumab shows efficacy in SustaIMM phase 2/3 trial

  • Ohtsuki M & al.
  • J Dermatol
  • 25.06.2019

  • von Brian Richardson, PhD
  • Clinical Essentials
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Risankizumab (Skyrizi) is associated with clinical improvement in Japanese patients with moderate to severe plaque psoriasis, according to results from the SustaIMM phase 2/3 trial.

Why this matters

  • Risankizumab, an interleukin 23 inhibitor, may represent a new treatment option for psoriasis.

Key results

  • At week 16, risankizumab was associated with a higher rate of ≥90% improvement in Psoriasis Area and Severity Index (PASI-90) compared with placebo (75.9% for 75 mg, 74.5% for 150 mg, 1.7% for placebo; P<.001 style="list-style-type:circle;">
  • Similar results were observed for static Physician Global Assessment score of clear/almost clear (86.2%, 92.7%, and 10.3%, respectively; P<.001 and pasi-100 respectively p>
  • At week 52, PASI-90 was achieved by 86.2% of patients in the risankizumab 75-mg group and 92.7% of patients in the risankizumab 150-mg group.
  • 52% of patients in the risankizumab 75-mg group, 56% of patients in the risankizumab 150-mg group, and 57% of patients in the placebo group experienced an adverse event during the first 16 weeks.
  • Study design

    • 171 patients were randomly assigned 2:2:1:1 to 75 mg risankizumab, 150 mg risankizumab, placebo with crossover to 75 mg risankizumab, or placebo with crossover to 150 mg risankizumab.
    • Funding: AbbVie; Boehringer Ingelheim.

    Limitations

    • Relatively small patient sample size.